top of page

ABOLOGIX signs a license agreement with Research Development Foundation for two monoclonal antibodies for oncology

  • branding425
  • Jul 20, 2018
  • 1 min read

Geneva, Switzerland, July 19, 2018 – Abologix has entered into an exclusive, worldwide in-license agreement with Research Development Foundation for two monoclonal antibodies for oncological indications that were developed at the University of Geneva with funding from Institut Clayton de la Recherche.

 
 
 

コメント


bottom of page